Martinis, Makeovers, and a Mission
To benefit the twoAM Fund
The twoAM Fund
Physicians supported by the twoAM Fund
The 2008 Neiman Marcus Martinis, Makeovers, and a Mission event directly supports innovative breast and ovarian cancer research at Dana-Farber Cancer Institute through the twoAM Fund.
Proceeds raised for twoAM will support two funds, Catalyst for a Cure, which provides funding for metastatic breast cancer research and Ovations for the Cure, which supports ovarian cancer research. Both funds have a singular mission: provide physicians and scientists with flexible funding to pursue the most promising research with the greatest potential to have an impact on treatments for patients with breast and ovarian cancer. The goal is to not only bridge the knowledge gap between the two diseases but use the combined power of this community to further innovative research to conquer both diseases. Following are examples of research that will be fueled by these funds:
Research Conducted by Catalyst for a Cure
- Distinguish if metastatic cell populations are largely similar to primary tumor cells, or if they are only related to small or rare subpopulations of primary tumor cells.
- Investigate the role, if any, that tumor stroma play in facilitating metastasis.
Research Conducted by Ovations for the Cure
- Explore possible genetic subtypes of ovarian cancer, with the potential to uncover molecular targets for new therapies.
- Determine why ovarian cancer cells become resistant to cisplatinum, a drug commonly used to combat ovarian cancer, which typically is an effective drug before cells develop resistance.
Physicians supported by the twoAM Fund
Ursula Matulonis, MD, and Eric Winer, MD, were the inspiration for the creation of the twoAM Fund. This funding will allow them to take directions and paths that can help to accelerate the pace in finding cures.
Ursula A. Matulonis, MD
Medical Director and Program Leader of the Gynecologic Oncology Program
Ursula Matulonis, MD, is an Assistant Professor of Medicine at Harvard Medical School and the Medical Director and Program Leader of the Gynecologic Oncology Program at Dana-Farber Cancer Institute. Her research is focused on gynecologic malignancies, and she is the Principal Investigator of several clinical trials for ovarian and cervical cancer.
Matulonis currently serves on the National Comprehensive Cancer Network Ovarian Cancer Recommendation and Guideline Committee, the Gynecologic Oncology Group Quality of Life Committee, and is the Medical Director and Advisor for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, and was named one of Boston's Best Physicians in Medical Oncology by Boston magazine.
After receiving her MD from Albany Medical College in New York she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber. She has been an attending physician at both Dana-Farber and Brigham and Women's Hospital since 1994.
Eric P. Winer, MD
Director of the Breast Oncology Center
Eric P. Winer, MD, is Director of the Breast Oncology Center and the Thompson Senior Investigator in Breast Cancer Research at Dana-Farber Cancer Institute. He is also an Associate Professor of Medicine at Harvard Medical School. He received his undergraduate and medical degrees from Yale University. He trained in internal medicine and served as chief resident at Yale-New Haven Hospital. Winer was a hematology-oncology fellow at Duke University Medical Center from 1987 through 1989 and then remained on the faculty at Duke until 1997.
In 1997, Winer moved to Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston. At Dana-Farber, Winer leads a multidisciplinary group of clinicians and investigators focused on caring for individuals with breast cancer and identifying new and better approaches to treatment.
Winer has participated in numerous practice guidelines panels and is the chair of the ASCO Technology Assessment Panel on the use of aromatase inhibitors in the adjuvant setting. Winer is co-chair of Cancer and Leukemia Group B (CALGB) Breast Committee. He serves as an editorial board member of the Journal of Clinical Oncology, Breast Cancer Research, Breast Cancer Research and Treatment, and Clinical Breast Cancer. He is a prolific contributor to the oncology scientific and clinical literature, contributing original research articles, editorials and textbook chapters.
Winer is also the Chief Scientific Advisor and Chair of the Scientific Advisory Board for Susan G. Komen for the Cure.
For more information:
Contact: Lauren Nash
Phone: (617) 632-3863
E-mail: lauren_nash@dfci.harvard.edu
Sponsor
